Back to search

Article

Aberrant Hydroxymethylation In Promoter Cpg Regions of Genes Related to the Cell Cycle and Apoptosis Characterizes Advanced Chronic Myeloid Leukemia Disease, Poor Imatinib Respondents And Poor Survival.

2021-02-15

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> There is strong evidence that disease progression, drug response and overall clinical outcome of CML disease are not only decided by BCR/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations. DNA hydroxymethylation is implicated in the development of variety of diseases. DNA hydroxymethylation in gene promoters plays an imp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
05dcdcf1-e484-596b-8949-de6f9d037724
DOI
10.21203/rs.3.rs-233868/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Aberrant Hydroxymethylation In Promoter Cpg Regions of Genes Related to the Cell Cycle and Apoptosis Characterizes Advanced Chronic Myeloid Leukemia Disease, Poor Imatinib Respondents And Poor Survival.DOI 10.21203/rs.3.rs-233868/v1
Epigenetic silencing of HOXA4 gene is associated with imatinib resistance, disease progression, BCR-ABL1 transcript type and smoking status among Chronic Myeloid Leukemia patientsSemantic proximity
DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.Semantic proximity
Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous LeukemiaSemantic proximity
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.Semantic proximity
Somatic mutations in myeloid transcription factors and in activated signaling genes predict the risk of treatment failure and progression to advanced phase in chronic myeloid leukemiaSemantic proximity
Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisisSemantic proximity
CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.Semantic proximity
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.Semantic proximity
Genome-wide DNA methylation in chronic myeloid leukaemiaSemantic proximity
Promoter hypermethylation of <i>p15</i><sup><i>INK</i>4<i>B</i></sup>, <i>HIC1</i>, <i>CDH1</i>, and <i>ER</i> is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patientsSemantic proximity
Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemiaSemantic proximity
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsSemantic proximity
Select a neighboring publication to make it the new centre.